Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms
Autore:
Bigatel, DA; Elmore, JR; Carey, DJ; Cizmeci-Smith, G; Franklin, DP; Youkey, JR;
Indirizzi:
GeisingerPAed Ctr, Vasc Surg Sect, Penn State Geisinger Med Ctr, Danville,Geisinger Med Ctr Danville PA USA 17822 tate Geisinger Med Ctr, Danville, Penn State Coll Med, Weis Ctr Res, Res Program, Danville, PA USA Penn State Coll Med Danville PA USA r Res, Res Program, Danville, PA USA
Titolo Testata:
JOURNAL OF VASCULAR SURGERY
fascicolo: 1, volume: 29, anno: 1999,
pagine: 130 - 138
SICI:
0741-5214(199901)29:1<130:TMMIBL>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
IN-SITU LOCALIZATION; IV COLLAGENASE; QUANTIFICATION; GELATINASE; BATIMASTAT; RAT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Elmore, JR GeisingerPAed Ctr, Vasc Surg Sect, Penn State Geisinger Med Ctr, Danville, Geisinger Med Ctr Danville PA USA 17822 ger Med Ctr, Danville,
Citazione:
D.A. Bigatel et al., "The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms", J VASC SURG, 29(1), 1999, pp. 130-138

Abstract

Purpose: Matrix metalloproteinases (MMPs) are proteolytic enzymes that candegrade the extracellular matrix of the aortic wall and lead to the formation of abdominal aortic aneurysms (AAAs). MMP inhibitors are a class of drugs that were developed to inhibit the activity of these proteolytic enzymesand are currently being studied as a way to control inflammatory diseases and cancer metastases. In this project, BB-94 (also known as batimastat), aspecific inhibitor of MMPs, was evaluated for its ability to control aneurysmal growth in an experimental AAA model. Methods: Experimental AAAs were created in a standard rat model by perfusing elastase into an isolated segment of aorta. The rats then were randomized to postoperatively undergo treatment daily with the MMP inhibitor BB-94 or the carrier control solution. Measurements of the aortic diameter were made at the time of initial surgery and at the time of death on postoperativeday 7. Aortic tissue was obtained for histologic examination, elastin evaluation, and MAC 1-alpha antibody staining to evaluate the inflammatory response. Results: The rats that underwent treatment with BB-94 had significantly less aneurysmal dilatation and a 113% increase in aortic size, as compared with the control rats that. had a 157% increase (P =.026). Histologic examination of the harvested aortas and grading of the elastin content showed a significantly greater elastin preservation in these rats that were treated with BB-94 as compared with the control rats (P =.036). MAC I-alpha antibody staining showed an attenuation of the inflammatory response in the group ofrats that underwent treatment with BB-94. Morphologic examination also revealed that the control of the inflammatory response correlated with the areas of elastin preservation. Conclusion: MMP inhibition with BB-94 limited the expansion of AAAs in this rat model. BB-94 appears to work not only as a direct pharmacologic inhibitor of MMPs but also as an interference with the inflammatory response seen in AAAs. Control of the inflammatory response was an unexpected result and may be related to the alterations in feedback mechanisms that are relatedto extracellular matrix degradation. Because this class of drugs is presently being developed to control the MMP inflammatory response seen with arthritis, these drugs also may ultimately serve as a pharmacologic treatment for patients with AAAs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 18:37:26